Diabetic mouse

Shizuru, J. A., Taylor-Edwards, C., Banks, B. A., Gregory, A. K., and Fathman, C. G. (1988). Immunotherapy of the nonobese diabetic mouse Treatment with an antibody to T-helper lymphocytes. Science 240, 659-662. 

The nonobese diabetic mouse (NOD), as well as the biobreeding (BB) rats are the two rodent models whose diabetes-related immunopathology is considered to be quite similar to that in humans. Studies in these animal models have revealed that autoreactive T cells that mediate islet 8 cell destruction belong to the Thl subset of T cells (produce IL-2 and IFN-7), whereas regulatory T cells are of the Th2 type (produce IL-4 and IL-10). Because Thl and Th2 cells are mutually inhibitory, there have been many trials using IL-4 and/or IL-10 for the prevention of autoimmune disease, like autoimmune diabetes, rheumatoid arthritis (Evans et al., 1996 Boyle et al., 1999), and inflammatory bowel disease (Rogy et al., 2000). 

Pennline, K.J., Roque-Gaffney, E. and Monahan, M. (1994) Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin. Immunol. Immuno-pathol., 71,169-175. 

Gallichan, W. S., Balasa, B., Davies, J. D. and Sarvetnick, N. (1999). Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. J. Immunol. 163, 1696-1703. 

Gocmen, C., Secilmis, A., Kumcu, E. K., Ertug, P. U., Onder, S., Dikmen, A., and Baysal, F. 2000. Effects of vitamin E and sodium selenate on neurogenic and endothelial relaxation of corpus cavernosum in the diabetic mouse. Eur. J. Pharmacol. 398 93-98. 

Connor, S.C. Hughes, M.G. Moore, G. Lister, C.A. Smith, S.A. Antidiabetic Rfficacy of BRL49653 a Potent Orally Active Insulin Sensitising Agent, Assessed in the C57BL/KsJ db/db Diabetic Mouse by Non Invasive Proton NMR Studies in Urine, J. Pharm. Pharmacol. 49,336-344 (1997). 

Lesniewski LA, Miller TA, Armstrong RB. 2003. Mechanisms of force loss in diabetic mouse skeletztl muscle. Muscle Nerve 28 493-500,... 

Galeano M, Altavilla D, Cucinotta D, et al. (2004). Recombinant human erythropoietin stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetes. 53(9) 2509-2517. 

From this study, it became clear that insulin releasing cells prepared by the gene transfection could control glucose metabolism of the diabetic mouse for a long period if cells were implanted in an appropriate form. Further studies, such as how to control cell growth, how to control the immune reaction and how to remove the implants when adverse effects are observed, are needed to apply gene therapy to clinically curing diabetes. 

Akita mousey insulin gene—mutated mouse db/db mouse, leptin receptor deficient mouse NOD mouse, nonobese diabetic mouse ob/ob mouse, obese mouse. 

PCL-PEG bFGF, EGF Nanofibers Wound heating promotion Enhanced epidermal cell proliferation Improved collagen and keratin synthesis Diabetic mouse Choi et al. (2011)... 

Ron, D., 2002. Proteotoxicity in the endoplasmic reticulum lessons from the Akita diabetic mouse. J. Clin. Invest. 109, 443—445. 

Wang, M., Kim, G.H., Wei, F., Chen, H., Altarejos, J. and Han, X. (2015) Improved method for quantitative analysis of methylated phosphatidylethanolamine species and its application for analysis of diabetic-mouse liver samples. Anal. Bioanal. Chem. 407, 5021-5032. 

Marti, G., Ferguson, M., Wang, J., Byrnes, C., Dieb, R., Qaiser, R., Bonde, R, Duncan, M. D., and Harmon, J. W. 2004. Electroporative transfection with Kgf-1 Dna improves wound healing in a diabetic mouse model. Gene Therapy, 11,1780-1785. 

Regeneration of Pancreatic B Cells of Type 1 Diabetic Mouse by Stem Cell... 

Keywords— diabetic mouse, mesenchymal stem cell, bone marrow, stem cell therapy, type 1 diabetes. 

---